Reduced exercise capacity appeared to be a consequence of cardiac and pulmonary changes, but not skeletal muscle alterations, in rat models of pulmonary hypertension (PH), according to recent research. While no functional problems with muscles could be observed despite obvious impairments in exercise capacity, significant cardiopulmonary dysfunction was already present.
As of April 15, Opsynvi (macitentan and tadalafil) — the first single-tablet treatment combination approved by the U.S. Food and Drug Administration (FDA) for pulmonary arterial hypertension (PAH) — is available to eligible patients in the U.S. through a specialty pharmacy network. With its launch, PAH patients who…
Despite more women being affected by pulmonary hypertension (PH), men with the cardiovascular disease had worse right ventricular function and lower odds of transplant-free survival relative to their female counterparts, a study found. In a large group of patients with various types of PH, sex differences in function of…
The U.S. Food and Drug Administration (FDA) has approved once-daily, fixed-dose tablets containing a combination of macitentan and tadalafil — to be marketed under the brand name Opsynvi — to treat adults with pulmonary arterial hypertension (PAH). The approval marks the first single-tablet treatment combination to become available…
Higher blood levels of the sclerostin protein were linked to cardiac abnormalities and an elevated risk of pulmonary hypertension (PH) in patients with kidney failure, according to a recent study. While sclerostin itself did not increase mortality risk, the presence of PH was a significant predictor of mortality…
An investigational fixed-dose combination of macitentan and tadalafil in a single tablet (M/T STCT) led to improvements in blood flow and reductions in a biomarker of heart failure for people with pulmonary arterial hypertension (PAH) who were treatment naïve or previously received monotherapies, according to final…
Echocardiogram (ECG) measures that indicate the heart’s right ventricle (RV) and the pulmonary arteries are working poorly together to send blood to the lungs may help predict the presence of pulmonary hypertension (PH) in people with a certain type of heart failure, a recent publication indicates.
A variant in the gene encoding the ALDH2 enzyme — fully known as aldehyde dehydrogenase 2 — was linked to an increased risk of pulmonary hypertension due to left heart disease (PH-LHD) among heart failure patients, a study in China found. Also called a polymorphism, meaning it involves one…
While about a quarter of pulmonary arterial hypertension (PAH) patients treated with the investigational therapy sotatercept tested positive for antibodies against it, the antibodies didn’t influence the therapy’s safety or effectiveness, according to a clinical trial analysis. The study, “The impact of immunogenicity on the pharmacokinetics,…
Add-on treatment with sotatercept, an investigational therapy for pulmonary arterial hypertension (PAH) now under regulatory review in the U.S., was predicted to prolong survival by about threefold relative to standard of care therapy alone in a recent analysis. The prediction model was built using short-term data from the…
Immune-related genes that could serve as potential therapeutic targets for pulmonary arterial hypertension (PAH) were identified in a recent study. Among them was ROCK2, which was found to have increased gene activity in PAH patients’ lung tissue and animal models. Therapeutic molecules to inhibit the ROCK2 protein are already being…
An inhaled formulation of imatinib in development by Aerami Therapeutics to treat pulmonary arterial hypertension (PAH), was safe and well tolerated with few systemic side effects among healthy adults in a Phase 1 trial. AER-901, which is delivered via a smart, breath-activated nebulizer, also showed a distinct absorption…
Get regular updates to your inbox.
